FDA27American Society of Hematology Annual Meeting and Exposition

The Food and Drug Administration is forecasting a requirement for the American Society of Hematology Annual Meeting and Exposition. This initiative supports the FDA Oncology Program by deploying subject matter experts to state, local, and international sites to share critical expertise in disease intervention, public health practices, and regulatory policies concerning oncology drug review and development. This annual conference focuses specifically on blood diseases and their impact on cancer, serving as a vital component of the Oncology Mission. The engagement is designed to enhance external relations, support recruiting efforts, and increase public awareness. The opportunity is categorized under NAICS code 611430 and is managed by the FDA's acquisition liaison.